CN109602811A - A kind of drug for treating coronary heart disease - Google Patents
A kind of drug for treating coronary heart disease Download PDFInfo
- Publication number
- CN109602811A CN109602811A CN201811610470.4A CN201811610470A CN109602811A CN 109602811 A CN109602811 A CN 109602811A CN 201811610470 A CN201811610470 A CN 201811610470A CN 109602811 A CN109602811 A CN 109602811A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart disease
- coronary heart
- treating coronary
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The present invention discloses a kind of Chinese medicine for treating coronary heart disease, is made of 10 parts of arillus longan, 15 parts of dried orange peel, 20 parts of pawpaw, 15 parts, 10 parts of radix achyranthis bidentatae, has a better effect to coronary heart disease.
Description
Technical field
The present invention relates to a kind of Chinese medicines for treating coronary heart disease.
Background technique
Coronary heart disease is a kind of most common heart disease, refers to that myocardial performance hinders because of caused by coronary artery stenosis, blood supply insufficiency
Hinder and (or) organic disease, therefore a kind of pain of squeezing property occurs for also known as ischemic heart disease (IHD), Symptoms thoracic cavity center
Bitterly, and can delay to neck, chin, arm, back and stomach, other possible symptoms of breaking-out have dizziness, shortness of breath, perspire, shiver, disliking
The heart and faintness, severe patient may be because heart failure and dead.Chinese medicine thinks: " the main blood of the heart, the lung main force ", is to say H&L
It is two organs adjacent in thoracic cavity, the heart in preceding lung rear, be responsible for promoting the movement of blood, the main breathing of lung by heart.This just causes
Research of the medical field to breathing and heart relationship, cardiopulmonary relationship complexity are interlocked, and the oxygen of heart consumption all derives from lung, lung
It goes wrong and directly results in heart disease.Chinese medicine thinks " cardiopulmonary are homologous ", and this is cardiopulmonary with the theoretical source controlled, and heart oxygen consumption itself accounts for
20% or so of entire human body, if lesion occurs in lung, anoxic is exactly heart at first.If long time mild anoxic can make the heart
Flesh shrinks enhancing, and increased heart rate causes coronary heart disease, and blood pressure, heart rate decline when severe depletion of oxygen, leads to myocardial necrosis, mental and physical efforts master declines
It exhausts or even sudden cardiac arrest.
Summary of the invention
The purpose of the present invention is to provide a kind of Chinese medicines of the good treatment coronary heart disease of therapeutic effect.
The invention adopts the following technical scheme:
A kind of Chinese medicine for treating coronary heart disease, is made of the bulk pharmaceutical chemicals of following parts by weight:
It is preferred that being made of the bulk pharmaceutical chemicals of following parts by weight:
10 parts of arillus longan, 15 parts of dried orange peel, 20 parts of pawpaw, 15 parts, 10 parts of radix achyranthis bidentatae.
The present invention mixes each raw material, is ground into fine powder, directly takes, four times a day, one time 2-3 grams, sent with warm water
Clothes.
Chinese medicine material reasonable compatibility of the invention, complements each other, and fundamentally treats coronary heart disease, and therapeutic effect is good.
Specific embodiment
Embodiment 1
The Chinese medicine for treating coronary heart disease is made of the bulk pharmaceutical chemicals of following parts by weight:
10 parts of arillus longan, 15 parts of dried orange peel, 20 parts of pawpaw, 15 parts, 10 parts of radix achyranthis bidentatae.
Typical case
Case 1: Zhang, male, 77 years old, there is uncomfortable in chest, pectoralgia, the symptom of shortness of breath, pectoralgia in people from Yiyang County, body in 1987
Compressing, stuffy or austerity are shown as, there is burn feeling, increased heart rate, blood pressure increase, perspire, and are diagnosed as angina pectoris coronary disease
Disease is not cured through many places treatment, and recurrent exerbation causes considerable distress to patient, starts within latter 1993 with the embodiment of the present invention 1
Drug treated, take 3 months Shi Haozhuan, the number that symptom occurs greatly reduces, and continues after taking 3 months, symptom disappears
Lose, check and restore normal, after do not recur.
Case 2: Xiao, male, 46 years old, there is palpitaition, out of breath, irritated, angina pectoris in Sanmenxia City people, when activity in 1997
Shape increases with fever, tachycardia, leucocyte, occurs heart failure when serious, is diagnosed as myocardial infarction type coronary heart disease, more
Punishment, which is treated, does not cure thoroughly, is treated upon somebody's introduction using the drug of embodiment 1 within 1998, good when taking 4 months
Turn, number of incidences greatly reduces, after continue to take 4 months, symptom disappears, check and restore normal, after do not recur.
It being counted through application clinic of the invention, the present invention treats patients with coronary heart disease 164, cures 135, it improves 20,
It is not cured 9, cure rate is up to 82.3%.
Coronary heart disease efficacy evaluation:
Cure: continuous three days, heart rate restored normal, and symptom disappears.
Improve: symptom mitigates.
Be not cured: heart rate, symptom are unchanged.
Claims (1)
1. a kind of Chinese medicine for treating coronary heart disease, it is characterised in that be made of the bulk pharmaceutical chemicals of following parts by weight:
10 parts of arillus longan, 15 parts of dried orange peel, 20 parts of pawpaw, 15 parts, 10 parts of radix achyranthis bidentatae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811610470.4A CN109602811A (en) | 2018-12-27 | 2018-12-27 | A kind of drug for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811610470.4A CN109602811A (en) | 2018-12-27 | 2018-12-27 | A kind of drug for treating coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109602811A true CN109602811A (en) | 2019-04-12 |
Family
ID=66012851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811610470.4A Withdrawn CN109602811A (en) | 2018-12-27 | 2018-12-27 | A kind of drug for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109602811A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102784A (en) * | 1994-02-28 | 1995-05-24 | 虹雨集团公司 | Chinese patent medicine for prevention and control of ischemic cardio-cerebral angiopathy |
| CN102119971A (en) * | 2011-03-01 | 2011-07-13 | 王延玲 | Traditional Chinese medicine for treating coronary heart disease |
| CN103656129A (en) * | 2013-11-20 | 2014-03-26 | 田博 | Traditional Chinese medicine composition for treating coronary heart disease |
| CN106390025A (en) * | 2016-10-30 | 2017-02-15 | 南宁多灵生物科技有限公司 | Drug for treating coronary heart disease |
-
2018
- 2018-12-27 CN CN201811610470.4A patent/CN109602811A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102784A (en) * | 1994-02-28 | 1995-05-24 | 虹雨集团公司 | Chinese patent medicine for prevention and control of ischemic cardio-cerebral angiopathy |
| CN102119971A (en) * | 2011-03-01 | 2011-07-13 | 王延玲 | Traditional Chinese medicine for treating coronary heart disease |
| CN103656129A (en) * | 2013-11-20 | 2014-03-26 | 田博 | Traditional Chinese medicine composition for treating coronary heart disease |
| CN106390025A (en) * | 2016-10-30 | 2017-02-15 | 南宁多灵生物科技有限公司 | Drug for treating coronary heart disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN109602811A (en) | A kind of drug for treating coronary heart disease | |
| CN106390025A (en) | Drug for treating coronary heart disease | |
| CN105412118A (en) | Western medicinal composition for treating acute or chronic dyspnea and preparation method of western medicinal composition | |
| Xu et al. | Remote postconditioning alone and combined with hypothermia improved postresuscitation cardiac and neurological outcomes in swine | |
| CN105213519A (en) | A kind of medicine and preparation method thereof for the treatment of prolapse of lumbar intervertebral disc, hyperosteogeny | |
| CN1331505C (en) | Mightiness pulse invigorating capsule and its preparation method | |
| CN102119971B (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN100540027C (en) | The Chinese medicine preparation of treatment tachycardia and complication thereof | |
| Osovska et al. | Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block-a case report | |
| CN105288325A (en) | Traditional Chinese medicine for treating arrhythmia caused by deficiency of both vital energy and yin | |
| CN106727610A (en) | A kind of Western medicine compound for treating vital myocarditis and its application | |
| Reynolds et al. | Circulatory versus respiratory deaths from pentothal sodium | |
| CN104116828B (en) | A kind of pharmaceutical composition of cure scapulohumeral periarthritis | |
| WO2017088177A1 (en) | Mussel adhesive protein product, and use thereof in preventing and suppressing neuronal inflammation | |
| CN1823890B (en) | Formula of oral Chinese medicine used for treating virus myocarditis | |
| CN103893346B (en) | One treats ARR Chinese medicine of motive asthenia type and preparation method thereof | |
| CN104188992B (en) | A kind of pharmaceutical composition for treating nephrotic syndrome | |
| JPWO2020166557A5 (en) | ||
| RU2265459C2 (en) | Prolonged microelectrostimulation method for treating the cases of acute myocardial infarction | |
| CN106606747A (en) | Traditional Chinese medicine composition for treating frequent ventricular premature beat | |
| CN109224028A (en) | The traditional Chinese compound medicine and preparation method for preventing and treating diabetic cardiomyopathy myocardial fibrosis | |
| Kong | Nursing supervision for using amiodarone hydrochloride injection to tachyarrhythmia patients | |
| Han et al. | Effects of Lüfukang Capsules () on Coronary Artery Ligation-Induced Arrhythmia in Dogs | |
| CN110393761A (en) | Chinese medicine composition, Chinese materia medica preparation and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190412 |